Navigation Links
Isis to Receive Up to $14 Million from Pfizer for Its Acquisition of Excaliard Pharmaceuticals
Date:11/22/2011

Phase 2, creating a strong clinical data package for this potentially breakthrough therapy.  Pfizer will provide additional drug development expertise and experience to support the continued advancement of EXC 001.  The market opportunity to treat disfiguring scars is very large, and we are pleased to have created an opportunity to participate in it through EXC 001 and Excaliard."

"CTGF has been an interesting target for fibrosis for years, and now we have the clinical data that Excaliard generated with EXC 001, which shows the importance of CTGF for the treatment of fibrotic disorders," said Brett Monia, Ph.D., Vice President, Drug Discovery and Corporate Development at Isis.  "We have been successfully pursuing systemic applications for CTGF, which differs from the local applications pursued by Excaliard, to treat a range of fibrotic diseases and look forward to advancing our program toward clinical development."

Isis and Excaliard entered into a collaboration in 2007 to discover and develop antisense drugs for the local treatment of fibrotic diseases, including scarring.  Excaliard is a private company funded by Rivervest Venture Partners, Alta Partners, Proquest Investments and Isis.  EXC 001 was co-discovered by Isis and Excaliard and developed by Excaliard for the treatment of skin scarring.  EXC 001 targets connective tissue growth factor, or CTGF, a growth factor that is over-expressed in damaged skin or tissue following a traumatic event.  In early 2011, Excaliard reported positive data from three Phase 2 studies demonstrating that EXC 001 significantly reduced scar severity in both hypertrophic and fine line scarring.  EXC 001 was safe and well tolerated in all subjects and is currently being evaluated in a Phase 2b study in patients following breast scar revision surgery.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its leadership position in antisense technology to discov
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Sundia Receives 2011 Zero2IPO Venture 50 Award
2. Amsterdam Molecular Therapeutics Receives Orphan Designation in the European Union for Hemophilia B Gene Therapy
3. Vascular Designs, Inc. Receives CE Mark Approval for Its IsoFlow™ Infusion Catheter to Target Cancerous Tumors
4. Qualitest Pharmaceuticals Receives FDA Approval for Acetaminophen and Codeine Phosphate Oral Solution USP, 120mg/12mg per 5mL
5. First Patient Receives FDA-Approved Telescope Implant for End-Stage Macular Degeneration
6. Ethicon Endo-Surgery Receives 510(k) Clearance for New ENSEAL® G2 Curved and Straight Tissue Sealers Line -- Broadest Range of Advanced Bipolar Tissue Sealers Available for Open and Minimally Invasive Surgery
7. Nephros Receives Initial FDA Response to 510(k) Application for Hemodiafiltration System
8. New Web Technology Now Allows for Pharmaceutical Reps to Receive Training on Their Desktops, Tablets, and Smartphones
9. IDEV Technologies Receives FDA Clearance for Its SUPERA VERITAS® 6 French Stent Delivery System
10. Augurix Diagnostics Receives the 2011 Debiopharm /Valais Award for its Point-of-care Diagnostic Test for the Early Detection of Celiac Disease
11. The Childrens Hospital of Philadelphia Receives Grand Challenges Explorations Funding
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... York , August 4, 2015 ... titled " Non-invasive Prenatal Testing (NIPT) Market (BambniTest, Harmony, ... Others) - Global Industry Analysis, Size, Volume, Share, Growth, ... According to a new market report published by Transparency ... Industry Analysis, Size, Volume, Share, Growth, Trends and Forecast ...
(Date:8/4/2015)... 04, 2015 Research ... addition of Jain PharmaBiotech,s new report "Animal ... their offering. This report describes and ... medicine and pharmaceuticals as well as improvement in ... in the application of biotechnology to manage genetic ...
(Date:8/4/2015)... Pharmaceuticals, Inc. ("ANI") (NASDAQ: ANIP ) today reported ... June 30, 2015 and updated its financial guidance for ... this morning, August 4, 2015, at 10:30 AM ET. ... by dialing (855) 582-8078. The conference ID is 90889796. ... revenues of $38.3 million, an increase of 118% as compared ...
Breaking Medicine Technology:Non-invasive Prenatal Testing (NIPT) Market Expected to Reach USD 2.38 Billion in 2022: Transparency Market Research 2Non-invasive Prenatal Testing (NIPT) Market Expected to Reach USD 2.38 Billion in 2022: Transparency Market Research 3Non-invasive Prenatal Testing (NIPT) Market Expected to Reach USD 2.38 Billion in 2022: Transparency Market Research 4Non-invasive Prenatal Testing (NIPT) Market Expected to Reach USD 2.38 Billion in 2022: Transparency Market Research 5Animal Biotechnology 2014-2024 - 2015 Technologies, Markets and Companies Analysis 2Animal Biotechnology 2014-2024 - 2015 Technologies, Markets and Companies Analysis 3ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 2ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 3ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 4ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 5ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 6ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 7ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 8ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 9ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 10ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 11ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 12ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 13ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 14ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 15ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 16
... Intellect Neurosciences, Inc. (OTCBB: ILNS), a biopharmaceutical company ... therapeutic agents for the treatment of Alzheimer,s and ... filed a response and request for continued examination ... 10/084,380, one of several applications pending in the ...
... VIEW, Calif., Nov. 3, 2011 VIVUS, Inc. (NASDAQ: ... chief financial officer, will present an overview of the ... The VIVUS presentation will take place at the ... at 9:30 a.m. MST.  A live webcast and 30-day ...
Cached Medicine Technology:Intellect Neurosciences Responds to Official Action by United States Patent and Trademark Office in Relation to its ANTISENILIN® Alzheimer's Patent Application 2Intellect Neurosciences Responds to Official Action by United States Patent and Trademark Office in Relation to its ANTISENILIN® Alzheimer's Patent Application 3
(Date:8/4/2015)... ... August 04, 2015 , ... It’s hard to look your ... Spa in Santa Barbara, CA is offering the solution by offering an underarm ... sweat and odor glands in the underarms. This simple and permanent solution usually ...
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... ... Kingdom and other international locations have shown a rise in binge drinking among ... link between binge drinking and depression, are continuing to examine trends and evidence ...
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... They say ... better understand certain health conditions, pictures and medical art can be essential. StayWell, a ... providers. , Krames Patient Education solutions have been used by physicians and other ...
(Date:8/4/2015)... ... August 04, 2015 , ... ... that Bruce McCalley joins its executive leadership team as Senior Vice President of ... at technology companies and expanding global markets with a special emphasis on the ...
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... ... nursing homes and other long-term care facilities, today announced details of the Advanced ... nursing homes and centers. , Providigm’s QAPI Accreditation program , introduced in ...
Breaking Medicine News(10 mins):Health News:Simple, Non-Invasive, Permanent Solution To Stop Underarm Sweating in Santa Barbara 2Health News:Simple, Non-Invasive, Permanent Solution To Stop Underarm Sweating in Santa Barbara 3Health News:DARA Responds To International Trends in Binge Drinking 2Health News:DARA Responds To International Trends in Binge Drinking 3Health News:StayWell Offers Instant Downloads, Licensing of Medical Art to Improve Patient Education 2Health News:StayWell Offers Instant Downloads, Licensing of Medical Art to Improve Patient Education 3Health News:SanusEO Hires Healthcare Technology Executive Bruce McCalley As Senior Vice President of Sales & Marketing 2Health News:SanusEO Hires Healthcare Technology Executive Bruce McCalley As Senior Vice President of Sales & Marketing 3Health News:Nursing Homes Achieving New Advanced Accreditation See Improved Measures of Quality, Better Occupancy Rates 2Health News:Nursing Homes Achieving New Advanced Accreditation See Improved Measures of Quality, Better Occupancy Rates 3
... with thousands of,herb-loving individuals, organizations and businesses across ... tomorrow, Oct. 13. The company will,continue to celebrate ... free 28-ct Mega Men(R) or Women,s Ultra Mega(R) ... National Herb Day recognizes the importance of ...
... the solution to providing ... STORRS, Conn., Oct. 12 A new report released,today ... low health,literacy to the United States economy is in the ... report, Low Health Literacy:,Implications for National Health Policy, the savings ...
... (Nasdaq: ARAY ), a global leader in the ... for its first quarter fiscal,year 2008, ending September 29, ... A conference call to review the results will ... be hosted by Euan S. Thomson, Ph.D., president and,chief ...
... might fight deadly pulmonary disease, experts say , , FRIDAY, Oct. ... cholesterol also slow the lung function loss that inevitably occurs ... researchers report. , The Harvard study included a group of ... at least twice between 1995 and 2005. , Those who ...
... be good for lowering cholesterol and maybe even fighting ... appear to slow decline in lung function in the ... in Boston, it may be statins anti-inflammatory and antioxidant ... were published in the second issue for October in ...
... Feeds the Soul and Whets the Appetite, RALEIGH, ... this weight-loss support group turned relay team, wondered what,their ... would be. Maria,Fernandez and the members of TeamGDT thought ... for the Cure", was a great answer,to not only ...
Cached Medicine News:Health News:GNC Honors Herb Day Tomorrow (and All Month Long) 2Health News:New Report Estimates Cost of Low Health Literacy Between $106 - $236 Billion Annually 2Health News:New Report Estimates Cost of Low Health Literacy Between $106 - $236 Billion Annually 3Health News:Accuray Incorporated to Report First Quarter Fiscal Year 2008 Financial Results 2Health News:Anti-Cholesterol Drugs Help Prevent Lung Decline 2Health News:Statins reduce loss of function, keeping old lungs young - even in smokers 2Health News:Good Food. Good Friends. Great Cause. 2
... Sirolimus-eluting Coronary Stent consists of ... "sirolimus", a controlled-release polymer, and ... Upon placement, sirolimus elutes into ... the process of neointimal hyperplasia, ...
PT wires combine the enhanced durability of a linear elastic nitinol distal core and a highly resilient polymer tip. This provides excellent access in difficult cases involving severe tortuosity, tig...
Forte Guide Wire w/Markers: Front line use, 1:1 torque, excellent steering and tracking, sharp vessel images, floppy and moderate support....
Forte Guide Wire w/Markers: Front line use, 1:1 torque, excellent steering and tracking, sharp vessel images, floppy and moderate support....
Medicine Products: